Cumberland Pharmaceuticals (CPIX) Short term Debt (2010 - 2024)

Cumberland Pharmaceuticals (CPIX) posted Short term Debt of $5.1 million for Q4 2024, down 14.84% sequentially from $6.0 million in Q3 2024.

Cumberland Pharmaceuticals (CPIX) Short term Debt (2010 - 2024) Analysis & Trends

Cumberland Pharmaceuticals has reported Short term Debt for 4 years, with the latest figure at $5.1 million in Q4 2024.

Quarterly Short term Debt changed N/A year-over-year to $5.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.1 million (changed N/A YoY) and the FY2024 annual result came in at $5.1 million, changed N/A from the prior year.
Short term Debt declined to $5.1 million in Q4 2024 per CPIX's latest filing, from $6.0 million in the prior quarter.
Over five years, Short term Debt peaked at $6.0 million in Q3 2024 and troughed at $2.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-
10	Cumberland Pharmaceuticals	117.01 Mn	113.14 Mn	-

Download Data